Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Tischkowitz

Showing results (201-210 of 258) with videos related to

Pageof 26
Sort By:
Breast Cancer Research : BCR|January 18, 2020
Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriersNasim Mavaddat, Antonis C Antoniou, Thea M Mooij, et al.
The Lancet. Oncology|August 8, 2020
Hereditary diffuse gastric cancer: updated clinical practice guidelinesVanessa R Blair, Maybelle McLeod, Fátima Carneiro, et al.
Breast Cancer Research and Treatment|July 24, 2010
International distribution and age estimation of the Portuguese BRCA2 c.156_157insAlu founder mutationAna Peixoto, Catarina Santos, Manuela Pinheiro, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|December 15, 2021
Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variantsHongyan Li, Christoph Engel, Miguel de la Hoya, et al.
JAMA|June 21, 2017
Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation CarriersKaroline B Kuchenbaecker, John L Hopper, Daniel R Barnes, et al.
American Journal of Human Genetics|October 31, 2025
BRCA1-, BRCA2-, and PALB2-related Fanconi anemia: Scope to expand disease phenotypic features and predict breast cancer risk in heterozygotesSharon E Johnatty, Emma Tudini, Michael T Parsons, et al.
The Lancet. Oncology|November 27, 2022
Genotype-first approach to identify associations between CDH1 germline variants and cancer phenotypes: a multicentre study by the European Reference Network on Genetic Tumour Risk SyndromesJosé Garcia-Pelaez, Rita Barbosa-Matos, Silvana Lobo, et al.
Medrxiv : the Preprint Server for Health Sciences|June 26, 2025
Analysis of <i>BRCA1</i>, <i>BRCA2</i> and <i>PALB2</i> related Fanconi anemia identifies scope to expand disease phenotypic features and predict breast cancer risk in heterozygotesSharon E Johnatty, Emma Tudini, Michael T Parsons, et al.
NPJ Breast Cancer|May 12, 2023
PREDICT validity for prognosis of breast cancer patients with pathogenic BRCA1/2 variantsTaru A Muranen, Anna Morra, Sofia Khan, et al.
British Journal of Cancer|April 19, 2023
Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2Denise G O'Mahony, Susan J Ramus, Melissa C Southey, et al.
Pageof 26

Showing results (201-210 of 258) with videos related to

Sort By:
Pageof 26
Breast Cancer Research : BCR|January 18, 2020
Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriersNasim Mavaddat, Antonis C Antoniou, Thea M Mooij, et al.
The Lancet. Oncology|August 8, 2020
Hereditary diffuse gastric cancer: updated clinical practice guidelinesVanessa R Blair, Maybelle McLeod, Fátima Carneiro, et al.
Breast Cancer Research and Treatment|July 24, 2010
International distribution and age estimation of the Portuguese BRCA2 c.156_157insAlu founder mutationAna Peixoto, Catarina Santos, Manuela Pinheiro, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|December 15, 2021
Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variantsHongyan Li, Christoph Engel, Miguel de la Hoya, et al.
JAMA|June 21, 2017
Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation CarriersKaroline B Kuchenbaecker, John L Hopper, Daniel R Barnes, et al.
American Journal of Human Genetics|October 31, 2025
BRCA1-, BRCA2-, and PALB2-related Fanconi anemia: Scope to expand disease phenotypic features and predict breast cancer risk in heterozygotesSharon E Johnatty, Emma Tudini, Michael T Parsons, et al.
The Lancet. Oncology|November 27, 2022
Genotype-first approach to identify associations between CDH1 germline variants and cancer phenotypes: a multicentre study by the European Reference Network on Genetic Tumour Risk SyndromesJosé Garcia-Pelaez, Rita Barbosa-Matos, Silvana Lobo, et al.
Medrxiv : the Preprint Server for Health Sciences|June 26, 2025
Analysis of <i>BRCA1</i>, <i>BRCA2</i> and <i>PALB2</i> related Fanconi anemia identifies scope to expand disease phenotypic features and predict breast cancer risk in heterozygotesSharon E Johnatty, Emma Tudini, Michael T Parsons, et al.
NPJ Breast Cancer|May 12, 2023
PREDICT validity for prognosis of breast cancer patients with pathogenic BRCA1/2 variantsTaru A Muranen, Anna Morra, Sofia Khan, et al.
British Journal of Cancer|April 19, 2023
Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2Denise G O'Mahony, Susan J Ramus, Melissa C Southey, et al.
Pageof 26